The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | MRD dynamics between arms of the FLAIR trial: comparing PB and BM MRD in patients with CLL
Talha Munir, MD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the measurable residual disease (MRD) dynamics observed in the different arms of the Phase III FLAIR trial (ISRCTN01844152). In patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib monotherapy or ibrutinib plus venetoclax, there is little to no difference between the MRD measured in peripheral blood (PB) and bone marrow (BM), and PB MRD can be used to predict less than 0.01% bone marrow disease (BM uMRD4). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
